Details

Autor(en) / Beteiligte

• Abrams, Rachel P. M.
• Yasgar, Adam
• Teramoto, Tadahisa
• Lee, Myoung-Hwa
• Dorjsuren, Dorjbal
• Eastman, Richard T.
• Malik, Nasir
• Zakharov, Alexey V.
• Li, Wenxue
• Bachani, Muzna
• Brimacombe, Kyle
• Steiner, Joseph P.
• Hall, Matthew D.
• Balasubramanian, Anuradha
• Jadhav, Ajit
• Padmanabhan, Radhakrishnan
• Simeonov, Anton
• Nath, Avindra

Titel

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors

Ist Teil von

• Proceedings of the National Academy of Sciences - PNAS, 2020-12, Vol.117 (49), p.31365-31375

Ort / Verlag

United States: National Academy of Sciences

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• When Zika virus emerged as a public health emergency there were no drugs or vaccines approved for its prevention or treatment. We used a high-throughput screen for Zika virus protease inhibitors to identify several inhibitors of Zika virus infection. We expressed the NS2B-NS3 Zika virus protease and conducted a biochemical screen for small-molecule inhibitors. A quantitative structure–activity relationship model was employed to virtually screen ∼138,000 compounds, which increased the identification of active compounds, while decreasing screening time and resources. Candidate inhibitors were validated in several viral infection assays. Small molecules with favorable clinical profiles, especially the five-lipoxygenase–activating protein inhibitor, MK-591, inhibited the Zika virus protease and infection in neural stem cells. Members of the tetracycline family of antibiotics were more potent inhibitors of Zika virus infection than the protease, suggesting they may have multiple mechanisms of action. The most potent tetracycline, methacycline, reduced the amount of Zika virus present in the brain and the severity of Zika virus-induced motor deficits in an immunocompetent mouse model. As Food and Drug Administration-approved drugs, the tetracyclines could be quickly translated to the clinic. The compounds identified through our screening paradigmhave the potential to be used as prophylactics for patients traveling to endemic regions or for the treatment of the neurological complications of Zika virus infection.